Bank of America’s Adverum Biotechnologies ADVM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-3,614
| Closed | -$16.4K | – | 7304 |
|
|
2025
Q3 | $16.4K | Sell |
3,614
-37,652
| -91% | -$111K | ﹤0.01% | 7113 |
|
|
2025
Q2 | $88.7K | Sell |
41,266
-9,956
| -19% | -$27.9K | ﹤0.01% | 6573 |
|
|
2025
Q1 | $224K | Buy |
51,222
+7,646
| +18% | +$34.5K | ﹤0.01% | 6111 |
|
|
2024
Q4 | $204K | Buy |
43,576
+6,094
| +16% | +$41K | ﹤0.01% | 6115 |
|
|
2024
Q3 | $263K | Sell |
37,482
-138,617
| -79% | -$1.01M | ﹤0.01% | 5878 |
|
|
2024
Q2 | $1.21M | Buy |
176,099
+10,604
| +6% | +$98.6K | ﹤0.01% | 4788 |
|
|
2024
Q1 | $2.34M | Sell |
165,495
-264,507
| -62% | -$4.02M | ﹤0.01% | 4321 |
|
|
2023
Q4 | $3.23M | Sell |
430,002
-46,917
| -10% | -$428K | ﹤0.01% | 3931 |
|
|
2023
Q3 | $7.15M | Sell |
476,919
-82,260
| -15% | -$1.48M | ﹤0.01% | 3058 |
|
|
2023
Q2 | $8.89M | Hold |
559,179
| – | – | ﹤0.01% | 2823 |
|
|
2023
Q1 | $4.01M | Sell |
559,179
-11
| -0% | -$78 | ﹤0.01% | 3726 |
|
|
2022
Q4 | $3.24M | Buy |
559,190
+558,185
| +55,541% | +$4.23M | ﹤0.01% | 3807 |
|
|
2022
Q3 | $10K | Buy |
1,005
+605
| +151% | +$7.95K | ﹤0.01% | 7224 |
|
|
2022
Q2 | $5K | Sell |
400
-2,689
| -87% | -$28.2K | ﹤0.01% | 7574 |
|
|
2022
Q1 | $40K | Sell |
3,089
-32,077
| -91% | -$469K | ﹤0.01% | 7258 |
|
|
2021
Q4 | $619K | Buy |
35,166
+13,673
| +64% | +$274K | ﹤0.01% | 5678 |
|
|
2021
Q3 | $467K | Sell |
21,493
-9,802
| -31% | -$250K | ﹤0.01% | 5698 |
|
|
2021
Q2 | $1.1M | Buy |
31,295
+12,577
| +67% | +$677K | ﹤0.01% | 4829 |
|
|
2021
Q1 | $1.85M | Sell |
18,718
-3,674
| -16% | -$441K | ﹤0.01% | 4330 |
|
|
2020
Q4 | $2.43M | Sell |
22,392
-16,278
| -42% | -$2.01M | ﹤0.01% | 3774 |
|
|
2020
Q3 | $3.98M | Sell |
38,670
-1,012
| -3% | -$152K | ﹤0.01% | 3117 |
|
|
2020
Q2 | $8.29M | Buy |
39,682
+35,942
| +961% | +$6.37M | ﹤0.01% | 2386 |
|
|
2020
Q1 | $366K | Buy |
3,740
+775
| +26% | +$90.4K | ﹤0.01% | 4727 |
|
|
2019
Q4 | $342K | Sell |
2,965
-193
| -6% | -$17K | ﹤0.01% | 5276 |
|
|
2019
Q3 | $172K | Sell |
3,158
-524
| -14% | -$59.1K | ﹤0.01% | 5752 |
|
|
2019
Q2 | $438K | Buy |
3,682
+2,283
| +163% | +$189K | ﹤0.01% | 5158 |
|
|
2019
Q1 | $73K | Sell |
1,399
-2,651
| -65% | -$107K | ﹤0.01% | 6034 |
|
|
2018
Q4 | $128K | Buy |
4,050
+2,633
| +186% | +$107K | ﹤0.01% | 5783 |
|
|
2018
Q3 | $85K | Buy |
1,417
+465
| +49% | +$26.1K | ﹤0.01% | 5957 |
|
|
2018
Q2 | $51K | Sell |
952
-953
| -50% | -$57.3K | ﹤0.01% | 6128 |
|
|
2018
Q1 | $111K | Buy |
+1,905
| New | +$119K | ﹤0.01% | 5686 |
|
|
2017
Q3 | – | Sell |
-755
| Closed | -$19K | – | 7019 |
|
|
2017
Q2 | $19K | Buy |
755
+348
| +86% | +$9.52K | ﹤0.01% | 6237 |
|
|
2017
Q1 | $11K | Sell |
407
-154
| -27% | -$4.38K | ﹤0.01% | 6509 |
|
|
2016
Q4 | $16K | Buy |
561
+481
| +601% | +$15.7K | ﹤0.01% | 6415 |
|
|
2016
Q3 | $3K | Sell |
80
-296
| -79% | -$11.2K | ﹤0.01% | 6724 |
|
|
2016
Q2 | $12K | Buy |
376
+276
| +276% | +$12.5K | ﹤0.01% | 6426 |
|
|
2016
Q1 | $5K | Sell |
100
-492
| -83% | -$27.5K | ﹤0.01% | 6561 |
|
|
2015
Q4 | $56K | Buy |
592
+435
| +277% | +$38.2K | ﹤0.01% | 5993 |
|
|
2015
Q3 | $13K | Sell |
157
-7,454
| -98% | -$952K | ﹤0.01% | 6472 |
|
|
2015
Q2 | $1.24M | Buy |
7,611
+7,609
| +380,450% | +$2.57M | ﹤0.01% | 3919 |
|
|
2015
Q1 | $1K | Sell |
2
-416
| -100% | -$176K | ﹤0.01% | 6768 |
|
|
2014
Q4 | $226K | Buy |
+418
| New | +$161K | ﹤0.01% | 5272 |
|
Bank of America's ADVM Position: Q4 2025 in Review
Bank of America sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 3,614 shares — an estimated $16.4K sold.
Bank of America first reported a position in ADVM in Q4 2014 and held it in 42 quarters. The position peaked at $8.89M in Q2 2023. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.
- Bank of America reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
- Bank of America sold 3,614 Adverum Biotechnologies shares in Q4 2025, an estimated $16.4K.
- Bank of America first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 42 quarters.
- Bank of America's Adverum Biotechnologies position peaked at $8.89M in Q2 2023.
- 0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.
Based on Bank of America's 13F filing for Q4 2025, filed 17 Feb 2026.